The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis

被引:0
作者
Hiligsmann, Mickael [1 ,2 ,3 ,4 ]
Boonen, Annelies [1 ,2 ]
Rabenda, Veronique [4 ]
Reginster, Jean-Yves [4 ]
机构
[1] Maastricht Univ, Dept Internal Med, Div Rheumatol, NL-6229 HX Maastricht, Netherlands
[2] Maastricht Univ, CAPHRI Res Inst, NL-6229 HX Maastricht, Netherlands
[3] Maastricht Univ, Dept Clin Epidemiol & Med Technol Assessment, NL-6229 HX Maastricht, Netherlands
[4] Univ Liege, Dept Publ Hlth Epidemiol & Hlth Econ, Liege, Belgium
关键词
adherence; compliance; cost-effectiveness; economic; osteoporosis; persistence; COST-EFFECTIVENESS; POSTMENOPAUSAL OSTEOPOROSIS; ORAL BISPHOSPHONATES; PATIENT ADHERENCE; FRACTURE RISK; TREATMENT PERSISTENCE; DIABETES-MELLITUS; ECONOMIC BURDEN; DRUG-THERAPY; IMPACT;
D O I
10.1586/ERP.12.8
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Adherence to medications is poor and suboptimal in many chronic diseases. Nonadherence can reduce treatment effectiveness and can have an impact on healthcare costs. As a consequence, it may alter the cost effectiveness of drug therapies. This article emphasizes the importance of integrating medication compliance and persistence into pharmacoeconomic evaluations, using osteoporosis as an example. A limited number of studies carried out to date have suggested important economic implications of poor adherence to osteoporosis medications. Therefore, compliance and persistence should be an integral part of clinical studies and pharmacoeconomic analyses in order to estimate the cost effectiveness of drug therapies in current community practice. Measuring adherence and incorporating it into health economic modeling may, however, pose particular challenges.
引用
收藏
页码:159 / 166
页数:8
相关论文
共 50 条
  • [1] Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations
    Hughes, Dyfrig
    Cowell, Warren
    Koncz, Tamas
    Cramer, Joyce
    VALUE IN HEALTH, 2007, 10 (06) : 498 - 509
  • [2] Cost-Effectiveness of Osteoporosis Screening Followed by Treatment: The Impact of Medication Adherence
    Hiligsmann, Mickael
    Gathon, Henry-Jean
    Bruyere, Olivier
    Ethgen, Olivier
    Rabenda, Veronique
    Reginster, Jean-Yves
    VALUE IN HEALTH, 2010, 13 (04) : 394 - 401
  • [3] Cost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women: impact of medication persistence and adherence
    Chen, Mingsheng
    Si, Lei
    Winzenberg, Tania M.
    Gu, Jieruo
    Jiang, Qicheng
    Palmer, Andrew J.
    PATIENT PREFERENCE AND ADHERENCE, 2016, 10 : 415 - 423
  • [4] Improving the Prediction of Medication Compliance The Example of Bisphosphonates for Osteoporosis
    Curtis, Jeffrey R.
    Xi, Juan
    Westfall, Andrew O.
    Cheng, Hong
    Lyles, Kenneth
    Saag, Kenneth G.
    Delzell, Elizabeth
    MEDICAL CARE, 2009, 47 (03) : 334 - 341
  • [5] Overcoming problems with adherence to osteoporosis medication
    Rabenda, Veronique
    Reginster, Jean-Yves
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2010, 10 (06) : 677 - 689
  • [6] The Economics of Improving Medication Adherence in Osteoporosis: Validation and Application of a Simulation Model
    Patrick, Amanda R.
    Schousboe, John T.
    Losina, Elena
    Solomon, Daniel H.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (09) : 2762 - 2770
  • [7] Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group
    Hiligsmann, M.
    Salas, M.
    Hughes, D. A.
    Manias, E.
    Gwadry-Sridhar, F. H.
    Linck, P.
    Cowell, W.
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 (12) : 2907 - 2918
  • [8] Osteoporosis medication adherence: Physician perceptions vs. patients' utilization
    Curtis, Jeffrey R.
    Cai, Qian
    Wade, Sally W.
    Stolshek, Bradley S.
    Adams, John L.
    Balasubramanian, Akhila
    Viswanathan, Hema N.
    Kallich, Joel D.
    BONE, 2013, 55 (01) : 1 - 6
  • [9] Medication adherence, first episode duration, overall duration and time without therapy: the example of bisphosphonates
    Roughead, Elizabeth E.
    Ramsay, Emmae
    Priess, Kym
    Barratt, John
    Ryan, Philip
    Gilbert, Andrew L.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 (01) : 69 - 75
  • [10] Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study
    Kendler, David L.
    Macarios, David
    Lillestol, Michael J.
    Moffett, Alfred
    Satram-Hoang, Sacha
    Huang, Joice
    Kaur, Primal
    Tang, En-Tzu
    Wagman, Rachel B.
    Horne, Rob
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2014, 21 (01): : 25 - 32